A5056639691- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Cardiac Arrest and Resuscitation
- Cardiac Health and Mental Health
- Prostate Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Hematopoietic Stem Cell Transplantation
- Genetic factors in colorectal cancer
- Inflammatory mediators and NSAID effects
- Cutaneous Melanoma Detection and Management
- Immunodeficiency and Autoimmune Disorders
- Glioma Diagnosis and Treatment
- Intensive Care Unit Cognitive Disorders
- Brain Metastases and Treatment
- Cervical Cancer and HPV Research
- Lung Cancer Research Studies
- Urinary and Genital Oncology Studies
- Genital Health and Disease
Sutter Health
2025
University of Iowa
2019-2022
University of Iowa Hospitals and Clinics
2018-2022
University of Iowa Holden Comprehensive Cancer Center
2020-2022
St. Luke's Hospital
2022
UnityPoint Health
2022
Baton Rouge General
2022
CHRISTUS St. Frances Cabrini Hospital
2022
University at Buffalo, State University of New York
2022
Huntsville Hospital
2022
Background: Cancer incidence (CI) and mortality vary significantly among countries are impacted by numerous factors including the country's income human development index (HDI). (CM) in adolescent young adult (AYA) population, age group of 15 - 39 years, has seen minimal improvement over past few decades. Our study aims to identify disparities this analyze influence HDI on these outcomes. Methods: We utilized GLOBOCAN database estimates for year 2022 185 or territories 36 cancer types trends...
BackgroundAndrogen deprivation therapy (ADT) is the gold standard for metastatic prostate cancer, which can be achieved either by surgical or medical castration. In this study, we evaluated trends of utilization castration and also assess survival differences patients who underwent when compared with those castration.Materials MethodsThe National Cancer Database was used to identify cancer from 2004 2014. Cochran-Armitage tests were temporal in proportion receiving relative Logistic Cox...
In 2011, ipilimumab was approved by the US Food and Drug Administration (FDA) for metastatic melanoma. Since its approval, numerous targeted therapies have been FDA. Population-based studies assessing survival benefit from these agents are lacking. We therefore carried out this study to compare 1-year, 2-year, median overall (OS) among melanoma patients in pretargeted post-targeted eras. This is a retrospective that utilized Surveillance, Epidemiology, End Results (SEER-18) database, version...
Recently antibiotic exposure has been associated with worse outcomes in patients undergoing treatment antibodies directed against programmed cell death protein-1 (PD-1). We reviewed data of 1264 enrolled at Melanoma Skin and Ocular Tissue Repositories University Iowa Hospitals Clinic. Reviewed included patient demographics, prior medical history, baseline hematologic disease parameters including progression-free survival (PFS) overall (OS). Cox regression models were used to determine...
Non-clear cell renal carcinoma (ccRCC) includes histologically and molecularly distinct subtypes such as papillary, chromophobe, collecting duct, sarcomatoid RCC, with an incidence ranging from 20% to 25%. Oncologic outcomes the role of adjuvant systemic therapy [vascular endothelial growth factor inhibitor (VEGFi) or immunotherapy] for non-ccRCC are not well-described.To assess survival in comparison ccRCC.The National Cancer Database was utilized identify patients non-metastatic RCC...
STK11 mutation (STK11m ) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of STK11m III NSCLC pts treated concurrent chemoradiation (CCRT) or without consolidation ICI unknown.Stage who received CCRT had known mutational status were included this retrospective study. data on the collected from 4 institutions. A cohort wild type (STK11w University Iowa served as a...
Introduction: Non-Hodgkin lymphoma is the seventh most common cancer in United States. It may involve any extranodal organ, although involvement of genitourinary (GU) tract accounts for <5% all primary lymphomas. Published GU literature currently limited to small case series and reports. The last substantial American was published 2009. Our objective characterize cases from our institution based on organ involved review relevant literature.Patients Methods: After institutional board...
For patients with metastatic RAS/RAF wild-type refractory colorectal cancer, the question of anti-EGFR therapy rechallenge often comes up after initial use. However, not all derive benefit. It is now well known that these tumors acquire mechanisms resistance in mitogen-activated protein kinase (MAPK) pathway, which can be detected on circulating tumor DNA (ctDNA)-based testing. We present a series who had serial testing post-EGFR blockade showing its feasibility and value. This would have...
5 Background: HPV is associated with 30 - 50% of penile cancers, some studies showing improved outcomes in these patients. This study evaluated the effect infection on cancer outcomes. Methods: The national database (NCDB) was utilized to identify tested patients at time diagnosis from 2004 – 2016. Chi-squared tests and Cox regression models were used analysis. Results: Out 486 squamous cell cancer, 139 (29%) +ve, 347 (71%) -ve. Greater than +ve < 65 years old, Caucasian, low-income areas...
288 Background: Androgen deprivation therapy (ADT) is the gold standard for metastatic prostate cancer (mPC) which can be achieved either by surgical or medical castration (SC, MC). In this study we evaluate trends of utilization SC and also assess survival difference compared to MC. Methods: National Cancer Database was used identify patients with mPC from 2004 2014. Logistic Cox regression models were utilized estimate odds effect treatment on overall (OS). Results: A total 33712 pts...
e15084 Background: Checkpoint inhibitors are approved as effective therapy in a number of malignancies. The response rates range between 20-40% various cancers. Predictive well prognostic clinical characteristics and bio-markers needed to identify the population that benefits with immunotherapy. Prior studies suggested presence hepatic metastases is marker poor prognosis. In this study patients treated checkpoint immunotherapy, we evaluated if it also predicts Other factors such age, BMI,...
9033 Background: STK11 mutation ( m ) in patients with stage IV NSCLC is associated inferior survival and poor response to immune check point inhibitors (ICI). The significance of (pts) III treated concurrent chemoradiation (CCRT) without consolidation ICI unknown. Methods: Patient demographics, disease characteristics, treatment received outcomes pts that harbor were retrospectively reviewed from 4 cancer centers. A cohort wild type (STK11 w the University Iowa served as a comparison group....
e12544 Background: Recent studies indicated that aryl-hydrocarbon receptor (AHR) modulators - such as omeprazole decrease breast cancer cell invasion among mice with estrogen negative (ER-) or triple (TN) cancer. Yet, it is unknown whether use decreases metastasis and improves survival in humans. The aim of this study was to assess the potential benefit on DFS ER- TN patients (pts) at a large academic center. Methods: A retrospective chart review conducted pts diagnosed between 2008 2016....
Abstract BACKGROUND Glioblastoma is one of the most aggressive and commonly encountered brain tumors. Standard care includes surgical resection with adjuvant or concurrent chemoradiation which predominantly based on adult clinical trials. Our study objective was to assess whether survival differed in AYA compared older adults. METHODS The National Cancer Database used identify patients at least surgically resected glioblastoma from 2004 2016. Cox regression models were utilized estimate...
131 Background: For patients with metastatic RAS/RAF wild-type refractory colorectal cancer anti-EGFR therapy can be reused in subsequent lines of therapy. However, it is not entirely clear if all derive benefit. Increasingly been recognized that these acquire mechanisms resistance which detected on circulating tumor DNA-based testing. We present a series who had serial testing post EGFR showing its feasibility and value. This would have implications for rechallenge. Methods: reviewed...